Development of Targeted Alpha Particle Therapy for Solid Tumors

Targeted alpha-particle therapy (TAT) aims to selectively deliver radionuclides emitting α-particles (cytotoxic payload) to tumors by chelation to monoclonal antibodies, peptides or small molecules that recognize tumor-associated antigens or cell-surface receptors. Because of the high linear energy transfer (LET) and short range of alpha (α) particles in tissue, cancer cells can be significantly damaged while causing minimal toxicity to surrounding healthy cells. Recent clinical studies have demonstrated the remarkable efficacy of TAT in the treatment of metastatic, castration-resistant prostate cancer. In this comprehensive review, we discuss the current consensus regarding the properties of the α-particle-emitting radionuclides that are potentially relevant for use in the clinic; the TAT-mediated mechanisms responsible for cell death; the different classes of targeting moieties and radiometal chelators available for TAT development; current approaches to calculating radiation dosimetry for TATs; and lead optimization via medicinal chemistry to improve the TAT radiopharmaceutical properties. We have also summarized the use of TATs in pre-clinical and clinical studies to date.

[1]  A. Maes,et al.  Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand Therapy , 2020, The Journal of Nuclear Medicine.

[2]  K. Gibson-Corley,et al.  Enhancing the efficacy of melanocortin 1 receptor-targeted radiotherapy by pharmacologically upregulating the receptor in metastatic melanoma. , 2019, Molecular pharmaceutics.

[3]  M. Morris,et al.  Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial , 2019, European journal of cancer.

[4]  M. Janssen,et al.  Patient Selection for Radium-223 Therapy in Patients With Bone Metastatic Castration-Resistant Prostate Cancer: New Recommendations and Future Perspectives. , 2019, Clinical genitourinary cancer.

[5]  E. Moros,et al.  Melanocortin 1 Receptor–Targeted α-Particle Therapy for Metastatic Uveal Melanoma , 2019, The Journal of Nuclear Medicine.

[6]  S. Dizdarevic,et al.  Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  S. Hasegawa,et al.  Targeted cancer cell ablation in mice by an α-particle-emitting astatine-211-labeled antibody against major histocompatibility complex class I chain-related protein A and B. , 2018, Biochemical and biophysical research communications.

[8]  S. Mirzadeh,et al.  Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  James M. Kelly,et al.  A Single Dose of 225Ac-RPS-074 Induces a Complete Tumor Response in an LNCaP Xenograft Model , 2018, The Journal of Nuclear Medicine.

[10]  Jason S. Lewis,et al.  Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma , 2018, Clinical Cancer Research.

[11]  C. Kratochwil,et al.  An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth , 2018, Current radiopharmaceuticals.

[12]  C. Decristoforo,et al.  Harmonization of U.S., European Union, and Canadian First-in-Human Regulatory Requirements for Radiopharmaceuticals: Is This Possible? , 2018, The Journal of Nuclear Medicine.

[13]  F. Bruchertseifer,et al.  225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  U. Haberkorn,et al.  Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  M. Budzevich,et al.  Structure and properties of DOTA-chelated radiopharmaceuticals within the 225Ac decay pathway. , 2018, MedChemComm.

[16]  S. Dizdarevic,et al.  223Ra-Dichloride in castration-resistant metastatic prostate cancer: improving outcomes and identifying predictors of survival in clinical practice , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  M. Brechbiel,et al.  Exploration of a F(ab')2 Fragment as the Targeting Agent of α-Radiation Therapy: A Comparison of the Therapeutic Benefit of Intraperitoneal and Intravenous Administered Radioimmunotherapy. , 2018, Cancer biotherapy & radiopharmaceuticals.

[18]  O. Sartor,et al.  Radium and other alpha emitters in prostate cancer , 2018, Translational andrology and urology.

[19]  H. Macapinlac,et al.  Prostate-specific antigen flare induced by 223RaCl2 in patients with metastatic castration-resistant prostate cancer , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  Bryan P Bednarz,et al.  Development and Validation of RAPID: A Patient-Specific Monte Carlo Three-Dimensional Internal Dosimetry Platform. , 2018, Cancer biotherapy & radiopharmaceuticals.

[21]  U. Haberkorn,et al.  Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control , 2018, The Journal of Nuclear Medicine.

[22]  M. Miederer,et al.  In vivo Evaluation of [225Ac]Ac-DOTAZOL for α-Therapy of Bone Metastases. , 2018, Current radiopharmaceuticals.

[23]  S. Mirzadeh,et al.  Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with 213Bi-substance P analogue , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  S. Mirzadeh,et al.  Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot study , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  S. Ferrone,et al.  212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models , 2018, International journal of molecular sciences.

[26]  B. Zeglis,et al.  The inverse electron-demand Diels-Alder reaction as a new methodology for the synthesis of 225Ac-labelled radioimmunoconjugates. , 2018, Chemical communications.

[27]  A. Shaw,et al.  Tumour heterogeneity and resistance to cancer therapies , 2018, Nature Reviews Clinical Oncology.

[28]  Ø. Bruland,et al.  Therapeutic Effect of α-Emitting 224Ra-Labeled Calcium Carbonate Microparticles in Mice with Intraperitoneal Ovarian Cancer12 , 2018, Translational oncology.

[29]  S. Lipton,et al.  Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 , 2018, Cell Death & Differentiation.

[30]  Yoichi M. Ito,et al.  Antitumor effects of radionuclide treatment using α-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[31]  C. Ferrone,et al.  212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models. , 2017, Nuclear medicine and biology.

[32]  James M. Kelly,et al.  An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy. , 2017, Angewandte Chemie.

[33]  N. Shore,et al.  eRADicAte: A Prospective Evaluation Combining Radium‐223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration‐Resistant Prostate Cancer , 2017, Clinical genitourinary cancer.

[34]  C. Cutler,et al.  More α Than β for Prostate Cancer? , 2017, The Journal of Nuclear Medicine.

[35]  Kashif Asghar,et al.  Bystander signaling via oxidative metabolism , 2017, OncoTargets and therapy.

[36]  C. Brayton,et al.  Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model , 2017, EJNMMI Research.

[37]  Youngkyoo Jung,et al.  Alpha Particle Enhanced Blood Brain/Tumor Barrier Permeabilization in Glioblastomas Using Integrin Alpha-v Beta-3–Targeted Liposomes , 2017, Molecular Cancer Therapeutics.

[38]  A. Mintz,et al.  IL13RA2 targeted alpha particle therapy against glioblastomas , 2017, Oncotarget.

[39]  W. Weichert,et al.  Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding , 2017, The Journal of Nuclear Medicine.

[40]  J. Karlsson,et al.  Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in in vitro and in vivo models of renal cell carcinoma , 2017, Oncotarget.

[41]  S. Ferrone,et al.  B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models. , 2017, Nuclear medicine and biology.

[42]  Kevin John,et al.  Targeted Alpha Therapy: The US DOE Tri-Lab (ORNL, BNL, LANL) Research Effort to Provide Accelerator-Produced $^{\mathrm{\mathbf{225}}}$\textbf{Ac for Radiotherapy} , 2017 .

[43]  E. Estey,et al.  Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 (225Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML) , 2016 .

[44]  B. Hadaschik Re: 225Ac-PSMA-617 for PSMA-Targeting Alpha-radiation Therapy of Patients with Metastatic Castration-resistant Prostate Cancer. , 2016, European urology.

[45]  S. Mirzadeh,et al.  Large scale accelerator production of 225Ac: Effective cross sections for 78-192MeV protons incident on 232Th targets. , 2016, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[46]  Karin M. Knudson,et al.  Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas’ sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation , 2016, Oncotarget.

[47]  C. Parker,et al.  Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial. , 2016, European urology.

[48]  F. Mottaghy,et al.  225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer , 2016, The Journal of Nuclear Medicine.

[49]  P. Chevallier,et al.  Radioimmunotherapy for Treatment of Acute Leukemia. , 2016, Seminars in nuclear medicine.

[50]  King Li,et al.  Preliminary Therapy Evaluation of 225Ac-DOTA-c(RGDyK) Demonstrates that Cerenkov Radiation Derived from 225Ac Daughter Decay Can Be Detected by Optical Imaging for In Vivo Tumor Visualization , 2016, Theranostics.

[51]  Seung-Chyul Hong,et al.  Recurrent Bleeding in Hemorrhagic Moyamoya Disease : Prognostic Implications of the Perfusion Status , 2016, Journal of Korean Neurosurgical Society.

[52]  C. Parker,et al.  Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  R. Baum,et al.  Influence of tumour size on the efficacy of targeted alpha therapy with 213Bi-[DOTA0,Tyr3]-octreotate , 2016, EJNMMI Research.

[54]  Brian M Zeglis,et al.  Site-Specifically Labeled Immunoconjugates for Molecular Imaging—Part 1: Cysteine Residues and Glycans , 2016, Molecular Imaging and Biology.

[55]  Brian M Zeglis,et al.  Site-Specifically Labeled Immunoconjugates for Molecular Imaging—Part 2: Peptide Tags and Unnatural Amino Acids , 2016, Molecular Imaging and Biology.

[56]  Constantin Mamat,et al.  The Radiochemical and Radiopharmaceutical Applications of Radium , 2016 .

[57]  E. Crawford,et al.  Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. , 2015, The Journal of urology.

[58]  M. Pomper,et al.  Nanoconjugation of PSMA-Targeting Ligands Enhances Perinuclear Localization and Improves Efficacy of Delivered Alpha-Particle Emitters against Tumor Endothelial Analogues , 2015, Molecular Cancer Therapeutics.

[59]  J. Barbet,et al.  Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model , 2015, Front. Med..

[60]  M. Brechbiel,et al.  Application of 212Pb for Targeted α-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation. , 2015, AIMS medical science.

[61]  Xiuling Li,et al.  Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues. , 2015, Bioconjugate chemistry.

[62]  R. Senekowitsch-Schmidtke,et al.  Fractionated intravesical radioimmunotherapy with 213Bi-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinoma , 2015, Cancer biology & therapy.

[63]  P. Conti,et al.  One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer. , 2015, Cancer biotherapy & radiopharmaceuticals.

[64]  H. Wolterbeek,et al.  A Critical Review of Alpha Radionuclide Therapy—How to Deal with Recoiling Daughters? , 2015, Pharmaceuticals.

[65]  F. Saad,et al.  ERA 223: A phase 3 trial of radium-223 dichloride (Ra-223) in combination with abiraterone acetate (abiraterone) and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone predominant metastatic castration-resistant prostate cancer (mCRPC). , 2015 .

[66]  T. Reiner,et al.  Cerenkov Luminescence Imaging for Radiation Dose Calculation of a 90Y-Labeled Gastrin-Releasing Peptide Receptor Antagonist , 2015, The Journal of Nuclear Medicine.

[67]  D. Scheinberg,et al.  Encapsulation of α-Particle–Emitting 225Ac3+ Ions Within Carbon Nanotubes , 2015, The Journal of Nuclear Medicine.

[68]  J. Kozempel,et al.  Prospective carriers of 223Ra for targeted alpha particle therapy , 2015, Journal of Radioanalytical and Nuclear Chemistry.

[69]  B. Miller,et al.  Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model. , 2015, Blood.

[70]  M. Brechbiel,et al.  Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease , 2015, mAbs.

[71]  Harrison H Barrett,et al.  The iQID camera: An ionizing-radiation quantum imaging detector. , 2014, Nuclear instruments & methods in physics research. Section A, Accelerators, spectrometers, detectors and associated equipment.

[72]  Chen-Yu Huang,et al.  Targeted alpha anticancer therapies: update and future prospects , 2014, Biologics : targets & therapy.

[73]  Sten Nilsson,et al.  Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. , 2014, The Lancet. Oncology.

[74]  K. Tatsch,et al.  EANM’15 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[75]  C. BoermanOtto,et al.  Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a (177)Lu-Labeled Peptide. , 2014 .

[76]  R. Tavaré,et al.  Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific ⁶⁴Cu-DOTA conjugation. , 2014, Protein engineering, design & selection : PEDS.

[77]  Julien Torgue,et al.  Dose Escalation and Dosimetry of First-in-Human α Radioimmunotherapy with 212Pb-TCMC-Trastuzumab , 2014, The Journal of Nuclear Medicine.

[78]  V. Subbiah,et al.  Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone , 2014, Experimental Hematology & Oncology.

[79]  D. Scheinberg,et al.  Efficient 1-Step Radiolabeling of Monoclonal Antibodies to High Specific Activity with 225Ac for α-Particle Radioimmunotherapy of Cancer , 2014, The Journal of Nuclear Medicine.

[80]  Bhushan L. Thakur,et al.  Molecular Imaging Aided Improvement in Drug Discovery and Development , 2014 .

[81]  U. Haberkorn,et al.  213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[82]  A. Mintz,et al.  Molecular targeted α-particle therapy for oncologic applications. , 2014, AJR. American journal of roentgenology.

[83]  S. Muyldermans,et al.  Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer , 2014, Expert opinion on drug delivery.

[84]  S. Fosså,et al.  Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. , 2014, The Lancet. Oncology.

[85]  F. Kraeber-Bodéré,et al.  Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and Melphalan chemotherapy. , 2014, Nuclear medicine and biology.

[86]  M. Piccart,et al.  A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease , 2014, Breast Cancer Research and Treatment.

[87]  J. Humm,et al.  Radiation Safety Considerations for the Use of 223RaCl2 DE in Men with Castration-resistant Prostate Cancer , 2014, Health physics.

[88]  H. Biersack,et al.  Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[89]  S. Shen,et al.  Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. , 2014, Cancer biotherapy & radiopharmaceuticals.

[90]  David J. Robertson,et al.  LnPO4 nanoparticles doped with Ac-225 and sequestered daughters for targeted alpha therapy. , 2014, Cancer biotherapy & radiopharmaceuticals.

[91]  H. Jadvar,et al.  Targeted &agr;-Particle Therapy of Bone Metastases in Prostate Cancer , 2013, Clinical nuclear medicine.

[92]  D. Scheinberg,et al.  Self-assembly of carbon nanotubes and antibodies on tumours for targeted, amplified delivery , 2013, Nature nanotechnology.

[93]  P. Moreau,et al.  213Bi Radioimmunotherapy with an Anti-mCD138 Monoclonal Antibody in a Murine Model of Multiple Myeloma , 2013, The Journal of Nuclear Medicine.

[94]  I. Navarro-Teulon,et al.  Comparison between Internalizing Anti-HER2 mAbs and Non-Internalizing Anti-CEA mAbs in Alpha-Radioimmunotherapy of Small Volume Peritoneal Carcinomatosis Using 2 1 2Pb , 2013, PloS one.

[95]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[96]  M. Brechbiel,et al.  Methodology for labeling proteins and peptides with lead-212 (212Pb). , 2013, Nuclear medicine and biology.

[97]  C. Bodet-Milin,et al.  Improvement of Radioimmunotherapy Using Pretargeting , 2013, Front. Oncol..

[98]  J. Pagel,et al.  Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model. , 2013, Blood.

[99]  S. Shen,et al.  First in human alpha radioimmunotherapy with 212Pb-TCMC-trastuzumab , 2013 .

[100]  A. Briel Innovative Diagnostics Enhances and Advances the Impact of In Vivo Small‐Animal Imaging in Drug Discovery and Pharmaceutical Development , 2013 .

[101]  S Marcatili,et al.  Development and validation of RAYDOSE: a Geant4-based application for molecular radiotherapy , 2013, Physics in medicine and biology.

[102]  T. Bäck,et al.  Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb , 2013, EJNMMI Research.

[103]  A. Gorden,et al.  Coordination chemistry with f-element complexes for an improved understanding of factors that contribute to extraction selectivity. , 2013, Inorganic chemistry.

[104]  C. Parker,et al.  Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. , 2013, Clinical genitourinary cancer.

[105]  H. Hanaoka,et al.  Renal brush border enzyme-cleavable linkages for low renal radioactivity levels of radiolabeled antibody fragments. , 2013, Bioconjugate chemistry.

[106]  David J. Robertson,et al.  Gold Coated Lanthanide Phosphate Nanoparticles for Targeted Alpha Generator Radiotherapy , 2013, PloS one.

[107]  M. Brechbiel,et al.  Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy. , 2013, Cancer biotherapy & radiopharmaceuticals.

[108]  M. Harrison,et al.  Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease , 2013, Cancer management and research.

[109]  D. Bellet,et al.  Immuno-SPET/CT and immuno-PET/CT: a step ahead to translational imaging , 2012, Clinical & Experimental Metastasis.

[110]  C. Ludgate Optimizing Cancer Treatments to Induce an Acute Immune Response: Radiation Abscopal Effects, PAMPs, and DAMPs , 2012, Clinical Cancer Research.

[111]  H. Song,et al.  Alpha Particle Emitter Radiolabeled Antibody for Metastatic Cancer: What Can We Learn from Heavy Ion Beam Radiobiology? , 2012 .

[112]  Young-Seung Kim,et al.  An overview of targeted alpha therapy , 2012, Tumor Biology.

[113]  J. Staffurth,et al.  A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. , 2012, European journal of cancer.

[114]  John L. Humm,et al.  Quantitative Modeling of Cerenkov Light Production Efficiency from Medical Radionuclides , 2012, PloS one.

[115]  E. Graves,et al.  The potential for Cerenkov luminescence imaging of alpha-emitting radionuclides , 2012, Physics in medicine and biology.

[116]  R. Senekowitsch-Schmidtke,et al.  Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[117]  I. Navarro-Teulon,et al.  Clinical radioimmunotherapy—the role of radiobiology , 2011, Nature Reviews Clinical Oncology.

[118]  C. Apostolidis,et al.  Targeted alpha therapy with 213Bi. , 2011, Current radiopharmaceuticals.

[119]  David A Scheinberg,et al.  Actinium-225 in targeted alpha-particle therapeutic applications. , 2011, Current radiopharmaceuticals.

[120]  B. Allen,et al.  Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma. , 2011, Immunotherapy.

[121]  J. Nesland,et al.  Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab , 2011, EJNMMI research.

[122]  D. Wilbur Chemical and radiochemical considerations in radiolabeling with α-emitting radionuclides. , 2011, Current radiopharmaceuticals.

[123]  M. Zalutsky,et al.  Astatine-211: production and availability. , 2011, Current radiopharmaceuticals.

[124]  S. Kennel,et al.  LaPO4 nanoparticles doped with actinium-225 that partially sequester daughter radionuclides. , 2011, Bioconjugate chemistry.

[125]  B. Myasoedov,et al.  Production of 225Ac and 223Ra by irradiation of Th with accelerated protons , 2011 .

[126]  J. Humm,et al.  Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody , 2011, Physics in medicine and biology.

[127]  J. Reubi,et al.  Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN). , 2011, Cancer research.

[128]  R. Senekowitsch-Schmidtke,et al.  177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[129]  Xiaoyuan Chen Integrin Targeted Imaging and Therapy , 2011, Theranostics.

[130]  J. Pagel,et al.  Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. , 2010, Blood.

[131]  Ronald G Blasberg,et al.  Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. , 2010, Cancer research.

[132]  S. Larson,et al.  Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia , 2010, Clinical Cancer Research.

[133]  L. Jacobsson,et al.  The α-Camera: A Quantitative Digital Autoradiography Technique Using a Charge-Coupled Device for Ex Vivo High-Resolution Bioimaging of α-Particles , 2010, The Journal of Nuclear Medicine.

[134]  David A Scheinberg,et al.  Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes , 2010, International journal of nanomedicine.

[135]  Jan Grimm,et al.  Cerenkov Luminescence Imaging of Medical Isotopes , 2010, Journal of Nuclear Medicine.

[136]  B. Wessels,et al.  MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy* , 2010, Journal of Nuclear Medicine.

[137]  Ravy K. Vajravelu,et al.  Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y. , 2009, Cancer research.

[138]  H. Kahu,et al.  Repeated Intraperitoneal α-Radioimmunotherapy of Ovarian Cancer in Mice , 2009, Journal of oncology.

[139]  M. Schwaiger,et al.  Intravesical α-Radioimmunotherapy with 213Bi-Anti-EGFR-mAb Defeats Human Bladder Carcinoma in Xenografted Nude Mice , 2009, Journal of Nuclear Medicine.

[140]  L. Jacobsson,et al.  Intraperitoneal α-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab′)2—A Phase I Study , 2009, Journal of Nuclear Medicine.

[141]  R. Senekowitsch-Schmidtke,et al.  Treatment of Peritoneal Carcinomatosis by Targeted Delivery of the Radio-Labeled Tumor Homing Peptide 213Bi-DTPA-[F3]2 into the Nucleus of Tumor Cells , 2009, PloS one.

[142]  J. Nesland,et al.  Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate 227Th-rituximab , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[143]  R. Storb,et al.  Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211. , 2009, Cancer research.

[144]  Yong Li,et al.  Inhibition of Micrometastatic Prostate Cancer Cell Spread in Animal Models By 213Bilabeled Multiple Targeted α Radioimmunoconjugates , 2009, Clinical Cancer Research.

[145]  J. Berenson,et al.  A Phase I Study of Samarium Lexidronam/Bortezomib Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma , 2009, Clinical Cancer Research.

[146]  G. Sgouros Alpha-particles for targeted therapy. , 2008, Advanced drug delivery reviews.

[147]  D. Scheinberg,et al.  Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications. , 2008, Advanced drug delivery reviews.

[148]  George Sgouros,et al.  Three-dimensional imaging-based radiobiological dosimetry. , 2008, Seminars in nuclear medicine.

[149]  R. Senekowitsch-Schmidtke,et al.  Preclinical Evaluation of the α-Particle Generator Nuclide 225Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors , 2008, Clinical Cancer Research.

[150]  Stavroula Sofou,et al.  Enhanced loading efficiency and retention of 225Ac in rigid liposomes for potential targeted therapy of micrometastases. , 2008, Bioconjugate chemistry.

[151]  T. Quinn,et al.  203Pb-Labeled α-Melanocyte–Stimulating Hormone Peptide as an Imaging Probe for Melanoma Detection , 2008, Journal of Nuclear Medicine.

[152]  R. Senekowitsch-Schmidtke,et al.  The potential of 211Astatine for NIS-mediated radionuclide therapy in prostate cancer , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[153]  T. Waldmann,et al.  Effective Treatment of Established Human Breast Tumor Xenografts in Immunodeficient Mice with a Single Dose of the α-Emitting Radioisotope Astatine-211 Conjugated to Anti-HER2/neu Diabodies , 2008, Clinical Cancer Research.

[154]  R. Coleman,et al.  Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6 , 2007, Journal of Nuclear Medicine.

[155]  D. Scheinberg,et al.  Enhanced Retention of the α-Particle-Emitting Daughters of Actinium-225 by Liposome Carriers , 2007 .

[156]  L. Jacobsson,et al.  Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice. , 2007, International journal of radiation oncology, biology, physics.

[157]  D. Bigner,et al.  Targeted α-Particle Radiotherapy with 211At-labeled Monoclonal Antibodies , 2007 .

[158]  D. Scheinberg,et al.  Tumor Targeting with Antibody-Functionalized, Radiolabeled Carbon Nanotubes , 2007, Journal of Nuclear Medicine.

[159]  R. Wahl,et al.  Three-Dimensional Radiobiologic Dosimetry: Application of Radiobiologic Modeling to Patient-Specific 3-Dimensional Imaging–Based Internal Dosimetry , 2007, Journal of Nuclear Medicine.

[160]  V. Tolmachev,et al.  Radioimmunotherapy With Astatine‐211 Using Chimeric Monoclonal Antibody U36 in Head and Neck Squamous Cell Carcinoma , 2007, The Laryngoscope.

[161]  A. Bosserhoff,et al.  Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma , 2007, Cancer biology & therapy.

[162]  T. Waldmann,et al.  Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1 , 2007, Proceedings of the National Academy of Sciences.

[163]  H. Lundqvist,et al.  Biodistribution of 211At labeled HER-2 binding affibody molecules in mice. , 2007, Oncology reports.

[164]  M. Brechbiel,et al.  Potentiation of High-LET Radiation by Gemcitabine: Targeting HER2 with Trastuzumab to Treat Disseminated Peritoneal Disease , 2007, Clinical Cancer Research.

[165]  S. Nilsson,et al.  High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the α-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities? , 2006, Clinical Cancer Research.

[166]  C. Mothersill,et al.  Radiation-Induced Bystander Effects: Evidence for an Adaptive Response to Low Dose Exposures? , 2006, Dose-response : a publication of International Hormesis Society.

[167]  S. Kneifel,et al.  Local Targeting of Malignant Gliomas by the Diffusible Peptidic Vector 1,4,7,10-Tetraazacyclododecane-1-Glutaric Acid-4,7,10-Triacetic Acid-Substance P , 2006, Clinical Cancer Research.

[168]  T. Nayak,et al.  213Bi-[DOTA0, Tyr3]Octreotide Peptide Receptor Radionuclide Therapy of Pancreatic Tumors in a Preclinical Animal Model , 2006, Clinical Cancer Research.

[169]  L. Jacobsson,et al.  Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[170]  M. Brechbiel,et al.  Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. , 2005, Cancer biotherapy & radiopharmaceuticals.

[171]  P. Beaumier,et al.  Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator. , 2005, Nuclear medicine and biology.

[172]  M. Schwaiger,et al.  Fractionated Locoregional Low-Dose Radioimmunotherapy Improves Survival in a Mouse Model of Diffuse-Type Gastric Cancer Using a 213Bi-Conjugated Monoclonal Antibody , 2005, Clinical Cancer Research.

[173]  D. Scheinberg,et al.  Renal tubulointerstitial changes after internal irradiation with alpha-particle-emitting actinium daughters. , 2005, Journal of the American Society of Nephrology : JASN.

[174]  T. Quinn,et al.  Melanoma Therapy via Peptide-Targeted α-Radiation , 2005, Clinical Cancer Research.

[175]  Manuel Bardiès,et al.  OEDIPE: a personalized dosimetric tool associating voxel-based models with MCNPX. , 2005, Cancer biotherapy & radiopharmaceuticals.

[176]  S. Fosså,et al.  First Clinical Experience with α-Emitting Radium-223 in the Treatment of Skeletal Metastases , 2005, Clinical Cancer Research.

[177]  Michael G Stabin,et al.  OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[178]  D. Scheinberg,et al.  Efforts to control the errant products of a targeted in vivo generator. , 2005, Cancer research.

[179]  O. Couturier,et al.  Cancer radioimmunotherapy with alpha-emitting nuclides , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[180]  L. Jacobsson,et al.  Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[181]  J. Gestin,et al.  Synthesis and metal complexation properties of Ph-DTPA and Ph-TTHA: novel radionuclide chelating agents for use in nuclear medicine. , 2005, Organic & biomolecular chemistry.

[182]  D. Scheinberg,et al.  Treatment of Neuroblastoma Meningeal Carcinomatosis with Intrathecal Application of α-Emitting Atomic Nanogenerators Targeting Disialo-Ganglioside GD2 , 2004, Clinical Cancer Research.

[183]  Peter S. Conti,et al.  Pegylated Arg-Gly-Asp Peptide: 64Cu Labeling and PET Imaging of Brain Tumor αvβ3-Integrin Expression , 2004 .

[184]  Ryan Park,et al.  MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. , 2004, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[185]  C. Divgi,et al.  Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[186]  L. Chappell,et al.  Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody. , 2004, Cancer biotherapy & radiopharmaceuticals.

[187]  D. Scheinberg,et al.  Alpha-Particle Emitting Atomic Generator (Actinium-225)-Labeled Trastuzumab (Herceptin) Targeting of Breast Cancer Spheroids , 2004, Clinical Cancer Research.

[188]  D. Scheinberg,et al.  Engineered Liposomes for Potential α-Particle Therapy of Metastatic Cancer , 2004 .

[189]  L. Jacobsson,et al.  Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[190]  D. Scheinberg,et al.  Targeted actinium-225 in vivo generators for therapy of ovarian cancer. , 2003, Cancer research.

[191]  L. Chappell,et al.  Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid for radiolabeling proteins. , 2003, Nuclear medicine and biology.

[192]  J. Roeske,et al.  Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[193]  Ursula Falkmer,et al.  A Systematic Overview of Radiation Therapy Effects in Skeletal Metastases , 2003, Acta oncologica.

[194]  D. Scheinberg,et al.  Design and synthesis of 225Ac radioimmunopharmaceuticals. , 2002, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[195]  A. Wu,et al.  Reduction of kidney uptake in radiometal labeled peptide linkers conjugated to recombinant antibody fragments. Site-specific conjugation of DOTA-peptides to a Cys-diabody. , 2002, Bioconjugate chemistry.

[196]  J. Humm,et al.  Targeted α particle immunotherapy for myeloid leukemia , 2002 .

[197]  T. Waldmann,et al.  Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. , 2002, Blood.

[198]  D. Scheinberg,et al.  Tumor Therapy with Targeted Atomic Nanogenerators , 2001, Science.

[199]  S. K. Imam Advancements in cancer therapy with alpha-emitters: a review. , 2001, International journal of radiation oncology, biology, physics.

[200]  M. Brechbiel,et al.  The development of the alpha-particle emitting radionuclides 212Bi and 213Bi, and their decay chain related radionuclides, for therapeutic applications. , 2001, Chemical reviews.

[201]  S. Mather,et al.  General aspects of the cellular response to low- and high-LET radiation , 2001, European Journal of Nuclear Medicine.

[202]  Dario Neri,et al.  Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin , 2001, European Journal of Nuclear Medicine.

[203]  M G Stabin,et al.  Monte Carlo MCNP-4B-based absorbed dose distribution estimates for patient-specific dosimetry. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[204]  M. Zalutsky,et al.  Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. , 2000, Current pharmaceutical design.

[205]  J. Sempau,et al.  DPM, a fast, accurate Monte Carlo code optimized for photon and electron radiotherapy treatment planning dose calculations. , 2000, Physics in medicine and biology.

[206]  L. Chappell,et al.  Synthesis, conjugation, and radiolabeling of a novel bifunctional chelating agent for (225)Ac radioimmunotherapy applications. , 2000, Bioconjugate chemistry.

[207]  G. Sgouros Long-lived alpha emitters in radioimmunotherapy: the mischievous progeny. , 2000, Cancer biotherapy & radiopharmaceuticals.

[208]  Håkan Andersson, Sture Lindegren, Tom Bäck, Lars Jacobss,et al.  The Curative and Palliative Potential of the Monoclonal Antibody MOv18 Labelled with 211At in Nude Mice with Intraperitoneally growing Ovarian Cancer Xenografts - A Long-Term Study , 2000 .

[209]  Y. Erdi,et al.  Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[210]  S. Larson,et al.  Preparation of α-Emitting 213Bi-Labeled Antibody Constructs for Clinical Use , 1999 .

[211]  S. Kennel,et al.  Comparison of 225actinium chelates: tissue distribution and radiotoxicity. , 1999, Nuclear medicine and biology.

[212]  A. Fayyazi,et al.  High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model. , 1999, Cancer research.

[213]  M. Jourdan,et al.  The myeloma cell antigen syndecan‐1 is lost by apoptotic myeloma cells , 1998, British journal of haematology.

[214]  D. Bigner,et al.  Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate. , 1997, Nuclear medicine and biology.

[215]  James M. Wilson,et al.  Recombinant adeno-associated virus for muscle directed gene therapy , 1997, Nature Medicine.

[216]  E. Silberstein Dosage and response in radiopharmaceutical therapy of painful osseous metastases. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[217]  O. Gansow,et al.  The use of 212Pb-labeled monoclonal antibody in the treatment of murine erythroleukemia. , 1996, International journal of radiation oncology, biology, physics.

[218]  R. McLendon,et al.  Radioimmunotherapy of Neoplastic Meningitis in Rats Using an α-Particle-emitting Immunoconjugate , 1994 .

[219]  T. Waldmann,et al.  Radioimmunotherapy of Nude Mice Bearing a Human Interleukin 2 Receptor α-expressing Lymphoma Utilizing the α-emitting Radionuclide-conjugated Monoclonal Antibody 212Bi-anti-Tac , 1994 .

[220]  P B Hoffer,et al.  Computerized three-dimensional segmented human anatomy. , 1994, Medical physics.

[221]  M. Charlier,et al.  Radiolytic footprinting. Beta rays, gamma photons, and fast neutrons probe DNA-protein interactions. , 1993, Biochemistry.

[222]  M. Brechbiel,et al.  Effective α-Particle-mediated Radioimmunotherapy of Murine Leukemia , 1992 .

[223]  T. Yokota,et al.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. , 1992, Cancer research.

[224]  Herbert Malamud,et al.  MIRD Primer for Absorbed Dose Calculations , 1989 .

[225]  F. Raes Description of the properties of unattached 218Po and 212Pb particles by means of the classical theory of cluster formation. , 1985, Health physics.

[226]  P. Marbach,et al.  SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. , 1982, Life sciences.

[227]  D T Goodhead,et al.  Mutation and inactivation of cultured mammalian cells exposed to beams of accelerated heavy ions. IV. Biophysical interpretation. , 1980, International journal of radiation biology and related studies in physics, chemistry, and medicine.

[228]  J. Figueiredo,et al.  Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. , 1979, Kidney international.

[229]  J. Hendry,et al.  Radiobiology for the Radiologist , 1979, British Journal of Cancer.

[230]  A. Kellerer,et al.  Criteria for the applicability of LET. , 1975, Radiation research.

[231]  L. H. Gray,et al.  The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy , 1955, British Journal of Cancer.

[232]  R. Diamond,et al.  An Ion-exchange Study of Possible Hybridized 5f Bonding in the Actinides1 , 1954 .

[233]  D. R. Corson,et al.  Artificially Radioactive Element 85 , 1940 .

[234]  M. Budzevich,et al.  Structure and properties of DOTA-chelated radiopharmaceuticals within the 225 Ac decay pathway , 2018 .

[235]  M. Schwaiger,et al.  [Intravesical radioimmunotherapy of carcinoma in situ of the urinary bladder after BCG failure]. , 2017, Der Urologe. Ausg. A.

[236]  D. Mankoff,et al.  The pre-clinical characterization of an alpha-emitting sigma-2 receptor targeted radiotherapeutic. , 2016, Nuclear medicine and biology.

[237]  M Slifstein,et al.  Imaging glutamate in schizophrenia: review of findings and implications for drug discovery , 2014, Molecular Psychiatry.

[238]  P. Anderson,et al.  Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223. , 2014, Advances in experimental medicine and biology.

[239]  Pardeep Kumar,et al.  Role of neuroimaging in drug development , 2014, Reviews in the neurosciences.

[240]  J. Barbet,et al.  ALPHA EMITTING RADIONUCLIDES AND RADIOPHARMACEUTICALS FOR THERAPY , 2014 .

[241]  W. Oyen,et al.  Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a (177)Lu-Labeled Peptide. , 2014, Cancer biotherapy & radiopharmaceuticals.

[242]  Jan Grimm,et al.  Cerenkov imaging. , 2014, Advances in cancer research.

[243]  Jan Grimm,et al.  Cerenkov imaging - a new modality for molecular imaging. , 2012, American journal of nuclear medicine and molecular imaging.

[244]  M. Brechbiel,et al.  Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72. , 2010, Cancer.

[245]  K. Polyak,et al.  Tumor heterogeneity: causes and consequences. , 2010, Biochimica et biophysica acta.

[246]  N. Edelstein,et al.  Summary and Comparison of Properties of the Actinide and Transactinide Elements , 2008 .

[247]  G. Denardo,et al.  Targeted radionuclide therapy. , 2008, Medical physics.

[248]  D. Bigner,et al.  Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies. , 2007, Nuclear medicine and biology.

[249]  D. Scheinberg,et al.  Enhanced retention of the alpha-particle-emitting daughters of Actinium-225 by liposome carriers. , 2007, Bioconjugate chemistry.

[250]  R. Senekowitsch-Schmidtke,et al.  Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in α-emitter therapy for disseminated ovarian cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[251]  Lester R. Morss,et al.  The chemistry of the actinide and transactinide elements , 2006 .

[252]  B. Wessels,et al.  MIRD Pamphlet No. 17: The Dosimetry of Nonuniform Activity Distributions—Radionuclide S Values at the Voxel Level , 2006 .

[253]  V. Lewington,et al.  Bone-seeking radionuclides for therapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[254]  S. Fosså,et al.  First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[255]  T. Quinn,et al.  Melanoma therapy via peptide-targeted {alpha}-radiation. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[256]  Ryan Park,et al.  MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. , 2004, Bioconjugate chemistry.

[257]  J. Bading,et al.  Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[258]  G. Henriksen,et al.  Thorium and actinium polyphosphonate compounds as bone-seeking alpha particle-emitting agents. , 2004, Anticancer research.

[259]  D. Scheinberg,et al.  Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[260]  D. Scheinberg,et al.  Engineered liposomes for potential alpha-particle therapy of metastatic cancer. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[261]  A. Dell'Acqua,et al.  Geant4—a simulation toolkit , 2003 .

[262]  P. Hudson,et al.  Engineered antibodies , 2003, Nature Medicine.

[263]  J. Humm,et al.  Targeted alpha particle immunotherapy for myeloid leukemia. , 2002, Blood.

[264]  L. Jacobsson,et al.  Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer. , 2001, Anticancer research.

[265]  T. Back,et al.  Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18. , 2000, Anticancer research.

[266]  L. Chappell,et al.  Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb. , 2000, Nuclear medicine and biology.

[267]  S. Larson,et al.  Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[268]  W E Bolch,et al.  MIRD pamphlet No. 17: the dosimetry of nonuniform activity distributions--radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[269]  D. Scheinberg,et al.  Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[270]  R. McLendon,et al.  Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate. , 1994, Cancer research.

[271]  M. Brechbiel,et al.  Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac. , 1994, Cancer research.

[272]  S. Mirzadeh,et al.  The Chemical Fate of 212Bi-DOTA Formed by β- Decay of 212Pb(DOTA)2-*** , 1993 .

[273]  M. Brechbiel,et al.  Effective alpha-particle-mediated radioimmunotherapy of murine leukemia. , 1992, Cancer research.

[274]  L. Mausner,et al.  In vivo generator for radioimmunotherapy , 1989 .

[275]  D. Schulte‐Frohlinde Mechanism of radiation-induced strand break formation in DNA and polynucleotides. , 1986, Advances in space research : the official journal of the Committee on Space Research.

[276]  B. J. Aylett Chemistry of the elements , 1985 .

[277]  J. Thacker,et al.  Mutation and inactivation of cultured mammalian cells exposed to beams of accelerated heavy ions. II. Chinese hamster V79 cells. , 1979, International journal of radiation biology and related studies in physics, chemistry, and medicine.

[278]  R. Cox,et al.  Mutation and inactivation of cultured mammalian cells exposed to beams of accelerated heavy ions. III. Human diploid fibroblasts. , 1979, International journal of radiation biology and related studies in physics, chemistry, and medicine.

[279]  D. Goodhead,et al.  Mutation and inactivation of cultured mammalian cells exposed to beams of accelerated heavy ions. I. Irradiation facilities and methods. , 1979, International journal of radiation biology and related studies in physics, chemistry, and medicine.

[280]  J. H. Lawrence,et al.  Alpha and Proton Heavy Particles and the Bragg Peak in Therapy. , 1964, Transactions of the American Clinical and Climatological Association.